U.S. flag

An official website of the United States government

Display Settings:

Format

Send to:

Choose Destination
Dostarlimab (Jemperli): CADTH Reimbursement Recommendation: Indication: Dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy [Internet].

Dostarlimab (Jemperli): CADTH Reimbursement Recommendation: Indication: Dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 May.

Table of contents


Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...